Data from a Phase 3 study revealed that ivonescimab demonstrates
a statistically significant and clinically meaningful improvement
in progression-free survival compared to pembrolizumab for patients
with PD-L1-positive advanced non-small cell lung cancer.
SAN
DIEGO, Sept. 8, 2024 /PRNewswire-PRWeb/ -- Data
from a Phase 3 study revealed that ivonescimab demonstrates a
statistically significant and clinically meaningful improvement in
progression-free survival compared to pembrolizumab for patients
with PD-L1-positive advanced non-small cell lung cancer. The
results were presented today at the International Association for
the Study of Lung Cancer (IASLC) 2024 World Conference on Lung
Cancer.
"The findings from the HARMONi-2 study
support the use of ivonescimab as a promising first-line treatment
option for patients with PD-L1-positive advanced NSCLC, potentially
offering a new and effective choice for managing this challenging
disease." -- Dr. Caicun Zhou
The HARMONi-2 study randomized 398 patients from 55 centers in
China to receive either
ivonescimab (20 mg/kg) or pembrolizumab (200 mg) every three weeks.
To be eligible for the trial, patients had to have untreated
locally advanced or metastatic NSCLC, ECOG PS 0-1, PD-L1 positive
(TPS greater than or equal to 1 percent) but negative EGFR
mutations or ALK rearrangements.
At the planned interim analysis, ivonescimab demonstrated a
median PFS of 11.14 months, significantly longer than the 5.82
months observed with pembrolizumab. This represents a 49 prercent
reduction in the risk of progression or death (stratified hazard
ratio {HR}, 0.51; 95% CI, 0.38 to 0.69; p less than 0.0001).
According to Dr. Caicun Zhou, Shanghai Pulmonary Hospital in
Shanghai, China, the benefit of
ivonescimab was consistent across various patient subgroups,
including those with squamous and non-squamous NSCLC, different
levels of PD-L1 expression, and those with liver or brain
metastases.
Dr. Zhou reported that safety profiles for both treatments were
comparable, with no new safety signals identified for ivonescimab.
Treatment-related serious adverse events (TRSAEs) occurred in 20.8
percent of patients receiving ivonescimab and 16.1 percent of those
receiving pembrolizumab. Grade ≥3 immune-related adverse events
were also similar between the two groups. In patients with squamous
cell carcinoma, grade 3 or higher-treatment-related adverse events
were comparable between two groups.
"The findings from the HARMONi-2 study support the use of
ivonescimab as a promising first-line treatment option for patients
with PD-L1-positive advanced NSCLC, potentially offering a new and
effective choice for managing this challenging disease," he said.
"These results highlight ivonescimab's potential as a new standard
of care."
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC)
is the only global organization dedicated solely to the study of
lung cancer and other thoracic malignancies. Founded in 1974, the
association's membership includes more than 10,000 lung cancer
specialists across all disciplines in over 100 countries, forming a
global network working together to conquer lung and thoracic
cancers worldwide. The association also publishes the Journal of
Thoracic Oncology, the primary educational and informational
publication for topics relevant to the prevention, detection,
diagnosis, and treatment of all thoracic malignancies. Visit
http://www.iaslc.org for more information.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world's largest
meeting dedicated to lung cancer and other thoracic malignancies,
attracting nearly 7,000 researchers, physicians and specialists
from more than 100 countries. The goal is to increase awareness,
collaboration and understanding of lung cancer, and to help
participants implement the latest developments across the globe.
The conference will cover a wide range of disciplines and unveil
several research studies and clinical trial results. For more
information, visit https://wclc2024.iaslc.org.
Media Contact
Chris Martin, IASLC, 6306702745,
cmartin@davidjamesgroup.com, www.iaslc.org
View original content to download
multimedia:https://www.prweb.com/releases/ivonescimab-outperforms-pembrolizumab-in-phase-3-study-for-first-line-treatment-of-pd-l1-positive-advanced-nsclc-in-harmoni-2-study-302241251.html
SOURCE IASLC